Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: BIOLOGICAL: nivolumab|DRUG: paclitaxel (PTX)|OTHER: nivolumab placebo|DRUG: anthracycline|DRUG: cyclophosphamide|DRUG: Endocrine Therapy|PROCEDURE: Surgery
Sponsor: Bristol-Myers Squibb